CASI Pharmaceuticals Inc (CASI)
5.74
+0.19
(+3.42%)
USD |
NASDAQ |
Nov 14, 16:00
5.89
+0.15
(+2.61%)
After-Hours: 17:55
CASI Pharmaceuticals Enterprise Value: 91.55M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 91.55M |
| November 12, 2024 | 92.32M |
| November 11, 2024 | 92.17M |
| November 08, 2024 | 90.48M |
| November 07, 2024 | 92.63M |
| November 06, 2024 | 95.03M |
| November 05, 2024 | 97.89M |
| November 04, 2024 | 100.59M |
| November 01, 2024 | 98.66M |
| October 31, 2024 | 99.05M |
| October 30, 2024 | 100.36M |
| October 29, 2024 | 100.59M |
| October 28, 2024 | 96.49M |
| October 25, 2024 | 106.24M |
| October 24, 2024 | 95.88M |
| October 23, 2024 | 90.77M |
| October 22, 2024 | 91.55M |
| October 21, 2024 | 90.77M |
| October 18, 2024 | 92.01M |
| October 17, 2024 | 89.69M |
| October 16, 2024 | 89.23M |
| October 15, 2024 | 92.01M |
| October 14, 2024 | 95.72M |
| October 11, 2024 | 95.72M |
| October 10, 2024 | 96.65M |
| Date | Value |
|---|---|
| October 09, 2024 | 99.28M |
| October 08, 2024 | 93.87M |
| October 07, 2024 | 94.64M |
| October 04, 2024 | 91.24M |
| October 03, 2024 | 89.91M |
| October 02, 2024 | 91.24M |
| October 01, 2024 | 92.47M |
| September 30, 2024 | 100.98M |
| September 27, 2024 | 98.66M |
| September 26, 2024 | 95.10M |
| September 25, 2024 | 87.22M |
| September 24, 2024 | 90.93M |
| September 23, 2024 | 99.74M |
| September 20, 2024 | 105.77M |
| September 19, 2024 | 106.85M |
| September 18, 2024 | 110.26M |
| September 17, 2024 | 112.26M |
| September 16, 2024 | 112.26M |
| September 13, 2024 | 116.59M |
| September 12, 2024 | 117.37M |
| September 11, 2024 | 122.47M |
| September 10, 2024 | 119.22M |
| September 09, 2024 | 109.02M |
| September 06, 2024 | 106.24M |
| September 05, 2024 | 107.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-7.265M
Minimum
Mar 20 2023
406.87M
Maximum
Jan 26 2021
108.73M
Average
88.83M
Median
Feb 15 2022
Enterprise Value Benchmarks
| Sinovac Biotech Ltd | -6.942B |
| Zai Lab Ltd | 2.423B |
| China SXT Pharmaceuticals Inc | -8.059M |
| Adagene Inc | 29.78M |
| LakeShore Biopharma Co Ltd | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.965M |
| Revenue (Quarterly) | 3.979M |
| Total Expenses (Quarterly) | 13.53M |
| EPS Diluted (Quarterly) | -0.52 |
| Gross Profit Margin (Quarterly) | 51.95% |
| Profit Margin (Quarterly) | -175.0% |
| Earnings Yield | -35.54% |
| Normalized Earnings Yield | -36.69 |